{"id":680940,"date":"2023-12-12T19:22:01","date_gmt":"2023-12-12T19:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680940"},"modified":"2023-12-12T19:22:01","modified_gmt":"2023-12-12T19:22:01","slug":"mesothelioma-pipeline-fda-approvals-clinical-trials-development-and-companies-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-pipeline-fda-approvals-clinical-trials-development-and-companies-2023_680940.html","title":{"rendered":"Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1702383639.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023\" src=\"https:\/\/www.abnewswire.com\/uploads\/1702383639.jpeg\" alt=\"Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Mesothelioma Pipeline Insight 2023<\/strong>&rdquo; report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Mesothelioma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Mesothelioma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.<\/li>\n<li>The leading companies working in the Mesothelioma Market include Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics, and others.<\/li>\n<li>Promising Mesothelioma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin, and others.<\/li>\n<li><strong>December 2023: <em>PrECOG LLC<\/em><\/strong> announced a study of Phase 3 clinical trials for Durvalumab. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.<\/li>\n<li><strong>December 2023: <em>AstraZeneca<\/em><\/strong> announced a study of Phase 3 clinical trials for Volrustomig, Pemetrexed, Carboplatin and Cisplatin. This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator&#8217;s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Mesothelioma Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Mesothelioma Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the Mesothelioma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Mesothelioma is a cancer caused by asbestos. It most commonly occurs in the linings of the lungs or the abdomen. The average life expectancy is 18 &ndash; 31 months after diagnosis, but prognosis may improve with treatment. Symptoms can include chest pain, shortness of breath and general fatigue.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Mesothelioma Therapeutics Assessment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Mesothelioma Preclinical and Discovery Stage Products<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>MesoPher: Amphera<\/li>\n<li>Durvalumab: AstraZeneca<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 50+ key companies which are developing the Mesothelioma therapies. The Mesothelioma companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Mesothelioma pipeline report covers around&nbsp;50+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Mesothelioma Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Mesothelioma Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Mesothelioma Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Mesothelioma Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Mesothelioma Companies- <em>Kissei Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, Oncovir, Inc., Sumitomo Pharma Oncology, Bayer, Trizell Ltd, Hutchison Medipharma Limited, Targovax, Polaris Group, Epizyme, Inc., Sanofi, AstraZeneca, Ascentage Pharma Group Inc., Shionogi, Eli Lilly and Company, Incyte Corporation, GlaxoSmithKline, Constellation Pharmaceuticals, Tmunity Therapeutics, Xencor Inc., NGM Biopharmaceuticals Inc., Inhibrx, Inc., VM Oncology, LLC, SOTIO Biotech AG, Atara Biotherapeutics<\/em>, and others.<\/li>\n<li>Mesothelioma Pipeline Therapies- <em>Nivolumab, Ipilimumab, Pemetrexed, MTG201, THOR-707, Pembrolizumab, IAG933, Volrustomig, Carboplatin<\/em>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Mesothelioma Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Mesothelioma Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Mesothelioma: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Mesothelioma &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Mesothelioma Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Durvalumab: AstraZeneca<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>TRC102: TRACON Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>SG001: CSPC ZhongQi Pharmaceutical Technology<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Mesothelioma Key Companies<\/li>\n<li>Mesothelioma Key Products<\/li>\n<li>Mesothelioma- Unmet Needs<\/li>\n<li>Mesothelioma- Market Drivers and Barriers<\/li>\n<li>Mesothelioma- Future Perspectives and Conclusion<\/li>\n<li>Mesothelioma Analyst Views<\/li>\n<li>Mesothelioma Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Mesothelioma Pipeline therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/mesothelioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Mesothelioma Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=mesothelioma-pipeline-fda-approvals-clinical-trials-development-and-companies-2023\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong>  +91-9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/persistent-epithelial-defect-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=mesothelioma-pipeline-fda-approvals-clinical-trials-development-and-companies-2023\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Mesothelioma Pipeline Insight 2023&rdquo; report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/mesothelioma-pipeline-fda-approvals-clinical-trials-development-and-companies-2023_680940.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-680940","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=680940"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680940\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=680940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=680940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=680940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}